AGIO Nasdaq Earnings call
AGIOS Pharmaceuticals, Inc. (AGIO) · Q2 2026 results
Share price: $32.82 · 2026-11-11
Results Q2 2026 vs Q1 2026 · previous quarter · published 30 Jul 2026 and 29 Apr 2026
Net loss widened on the previous quarter. Management sounded about as positive as a typical company call, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2026
Outlook given
Net income -100.7M vs -99.1M
Revenue +115.7%
2 · How management spoke
Typical
More upbeat than 55% of company calls
Answers to analysts: restrained, in line with the script.
Similar to last call.
3 · What stood out
Guidance
AGIO ended the quarter with approximately $1 billion in cash and marketable securities, providing financial flexibility.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$32.82
close of 2026-11-11
Revenue growth, 3 years
+56.0% a year
compound annual rate (CAGR)
Free cash flow 2023
−$0.3B
Free cash flow 2024
−$0.4B
Free cash flow 2025
−$0.4B
Read between the lines
-
Key theme
AGIO updated guidance to expect Q2 2026 prescription growth and revenue as its launch enters a new phase.
Source quote
“As we've been seeing consistently across rare disease launches, the shape of new patient starts naturally moderates as adoption broadens... ...anticipated demand for thalassemia in Europe following approval and continued consistent early demand for thalassemia in the GCC. We continue to expect quarter-to-quarter revenue variability, reflecting order timing, inventory movement and gross to net dynamics.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“The first quarter benefited from a strong prelaunch anticipation and momentum built in the period leading to approval following the more than 3-month PDUFA delay.”
“We are executing against multiple drivers of value creation, including the launch of AQVESME in thalassemia, the potential expansion of Mitapivat into sickle cell disease and a pipeline that continues...”
“We're advancing Mitapivat toward a potential approval in sickle cell disease, which represents an important opportunity to expand our PK activation franchise and a potential next growth driver for the...”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Metric | Q2 2026period end 2026-06-30 | Q1 2026period end 2026-03-31 | Change | Q2 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 44.7M | 20.7M | +115.7% | 12.5M | +259.3% |
| Gross profit | 41.7M | 19.4M | +114.9% | 10.8M | +288.3% |
| Operating income | -110.6M | -110.0M | Loss widened | -127.1M | Loss narrowed |
| Net income | -100.7M | -99.1M | Loss widened | -112.0M | Loss narrowed |
| EPS | -1.69 | -1.69 | ±0% | -1.93 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — | 2.9 | — |
Topics
Most discussed now
- New Agios Pharmaceuticals also continues to apply a disciplined approach to portfolio management, making focused investment decisions and…
- Full year operating expenses are expected to remain approximately flat versus 2025, excluding the $25 million upfront payment associated…
- Performance reflected continued growth in thalassemia demand and solid commercial execution.
- Agios Pharmaceuticals remains committed to bringing Mitapivat to patients with sickle cell disease and recently dosed the first patient in…
- Agios is anchored by a growing commercial business and supported by a pipeline spanning multiple development stages and disease...
Faded since Q1 2026
- Fading Launch execution in rare diseases is complex and the early progress Agios Pharmaceuticals is seeing reflects both strong...
- Fading Please advance to the next slide, and I'll turn it over to Tsveta to cover commercial highlights and early AQVESME's...
- Fading Agios Pharmaceuticals reported $81 million in R&D expense in the first quarter, an increase of roughly $8 million from prior year...
- Fading This is in line with Agios Pharmaceuticals' expectations given early market access dynamics ahead of securing government procurement.
Latest announcements
Official filings, newest first.
- Results of operations · SEC 8-K
- Director or officer change; Shareholder vote results · SEC 8-K
- Results of operations · SEC 8-K
- Results of operations · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K